Henry H. Hsu

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.